Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome
Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators will investigate the impact and the related mechanism of
metformin treatment on cognitive impairment of schizophrenia co-morbid metabolic syndrome
(Sch-MetS). The study will recruit 40 Sch-MetS patients, 40 patients with schizophrenia only,
and 40 patients with schizophrenia and higher risk factors for MetS. Then these patients will
be randomized to metformin group or non-metformin control group (20 patients per arm) for 24
weeks clinic trial. Clinical assessment will be done at screen/baseline, 4 week, 12 weeks and
24 week. The specific aims are to compare metformin group versus controls on: 1) clinical
core symptoms; 2) cognition. Biological samples also will be collected, and stored to
research related mechanisms.